Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed melanoma of cutaneous origin
Participants with BRAFV600 mutation-positive, cutaneous melanoma (either pathologic Stage IIC or Stage III according to AJCC Staging Criteria version 7 that has been completely resected
BRAF V600 mutation status of the current primary tumor or involved lymph node determined to be positive using the cobas BRAF V600 mutation test
Surgically rendered free of disease within 90 days of randomization
Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Life expectancy of at least 5 years
Fully recovered from the effects of any major surgery or significant traumatic injury prior to the first dose of study treatment
Adequate hematologic, hepatic, and renal function
You may not be if
History of any systemic or local therapy (e.g., chemotherapy, biologic or targeted therapy, hormonal therapy, or photodynamic therapy) for the treatment or prevention of melanoma, including interferon alpha-2b and pegylated interferon alpha-2b
History of limb perfusion therapy
History of radiotherapy for the treatment of melanoma
Invasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first dose of study treatment
Family history of inherited colon cancer syndromes
Known personal history of \>3 adenomatous colorectal polyps or a personal history of adenomatous colorectal polyp(s) \>2 centimeters (cm) in size
History of or current clinical, radiographic, or pathologic evidence of in-transit metastases, satellite, or microsatellite lesions
History of or current clinical, radiographic, or pathologic evidence of recurrent lymph node involvement after resection of a primary melanoma with lymph node involvement at any time in the past
History of local and/or regional and/or distant melanoma recurrence
History or current radiographic or pathologic evidence of distant metastases
History of clinically significant cardiac or pulmonary dysfunction
Major surgical procedure or significant traumatic injury within 4 weeks prior to first dose of study treatment
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus
